Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dusa Patent Suit Challenges Compounding Of Levulan

This article was originally published in The Pink Sheet Daily

Executive Summary

New England Compounding Center’s compounding of aminolevulinic acid HCl goes beyond the activities permitted under the FD&C Act, Dusa maintains. The company has also told FDA about its concerns.
Advertisement

Related Content

FDA’s Compounding Oversight: What Price Safety?
Dusa Settles Compounding Suit
Dusa Settles Compounding Suit
Compounding Pharmacists Must Use Disclaimer Under Settlement With Chiron
Compounding Pharmacists Must Use Disclaimer Under Settlement With Chiron
FDA Compounding Policy To Have Day In Court In December
FDA Cites Respi Care As Part Of Pharmacy Compounding Enforcement
Pharmacy's Compounding Resembles Rx Manufacturing Operation, FDA Says
FDA Drug Compounding Enforcement Continues With Teregen Labs Citation
FDA Drug Compounding Enforcement Continues With Teregen Labs Citation

Topics

Advertisement
UsernamePublicRestriction

Register

PS058475

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel